Description
Description: Resof Total is a combination medication that contains two active ingredients: Velpatasvir and Sofosbuvir. Manufactured by Dr. Reddy’s Laboratories Ltd., each tablet of Resof Total provides 100 mg of Velpatasvir and 400 mg of Sofosbuvir.
Indications: Resof Total is primarily used in the treatment of chronic hepatitis C virus (HCV) infection in adults. It is indicated for use in patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection, including those with compensated cirrhosis or with human immunodeficiency virus (HIV) coinfection.
Mechanism of Action: Velpatasvir and Sofosbuvir are direct-acting antiviral agents that work by interfering with the replication of the hepatitis C virus. Velpatasvir inhibits the NS5A protein, while Sofosbuvir inhibits the NS5B polymerase enzyme. Together, they prevent the virus from multiplying and help clear the infection from the body.
Administration: Resof Total tablets are administered orally, typically taken once daily with or without food. The recommended dosage and duration of treatment may vary depending on factors such as the genotype of the hepatitis C virus, the extent of liver damage, and prior treatment history. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare provider.
Dosage and Treatment Plan: The standard dosage of Resof Total is one tablet taken orally once daily. The duration of treatment may range from 12 to 24 weeks, depending on the specific genotype of HCV and the patient’s treatment history. The treatment regimen may also include other medications such as ribavirin or other antiviral agents, especially in certain patient populations.
Side Effects: Common side effects associated with Resof Total may include fatigue, headache, nausea, insomnia, diarrhea, and rash. More serious side effects such as liver toxicity or allergic reactions are rare but may occur. It is essential to report any adverse reactions to a healthcare provider promptly.
Precautions:
- Resof Total should be used with caution in patients with pre-existing liver or kidney impairment, as well as those with a history of hypersensitivity to Velpatasvir, Sofosbuvir, or any other components of the formulation.
- It may interact with other medications, so it is important to inform the healthcare provider about all current medications, including over-the-counter drugs and supplements.
- Pregnant or breastfeeding women should avoid using Resof Total, as its safety in these populations has not been established.
Consultation with a Healthcare Provider: Before starting treatment with Resof Total, individuals should consult with a healthcare provider or qualified hepatologist. They can provide guidance on proper usage, dosage, and potential risks associated with the medication. Regular monitoring and evaluation are essential to ensure safety and efficacy during treatment.
Reviews
There are no reviews yet.